Πλοήγηση ανά Θέμα "Drug infusion"
Αποτελέσματα 1-8 από 8
-
Article
Biweekly administration of 24-h infusion of irinotecan followed by a 1-h infusion of docetaxel: A phase I study
(2004)We developed a chemotherapy combination regimen based on preclinical data suggesting synchronization of cancer cells in G2/M phase when exposed to irinotecan over a protracted period. This phase I study aimed to determine ...
-
Article
Glufosfamide administered using a 1-hour infusion given as first-line treatment for advanced pancreatic cancer. A phase II trial of the EORTC-new drug development group
(2003)The activity of glufosfamide (β-D-glucopyranosyl-N,N′ -di-(2-chloroethyl)-phosphoric acid diamide) against pancreatic cancer was investigated in a multicentre, phase II clinical study. Chemotherapy-naïve patients with ...
-
Article
Interaction pharmacokinetis of pegylated liposomal doxorubicin (Caelyx) on coadministration with paclitaxel or docetaxel
(2004)Purpose: To investigate the pharmacokinetics of polyethylene glycol-coated liposomal doxorubicin (PLD, Caelyx) when given as a single agent and in combination with the taxanes paclitaxel or docetaxel in humans. Methods: ...
-
Article
Phase I study of etoposide, cisplatin and irinotecan triplet in patients with advanced-stage small-cell lung cancer
(2005)The irinotecan-cisplatin combination has emerged as a new standard for the treatment of advanced-stage small-cell lung cancer (AS-SCLC). To move forward we developed a 3-day regimen of cisplatin, etoposide and irinotecan. ...
-
Article
Phase II study of docetaxel-vinorelbine in platinum-resistant, paclitaxel-pretreated ovarian cancer
(2003)Background: This multicenter, prospective phase II study evaluated the safety and efficacy of the combination of docetaxel and vinorelbine in patients with platinum-resistant, paclitaxel-pretreated recurrent ovarian cancer. ...
-
Article
Randomized comparison of early versus late hyperfractionated thoracic irradiation concurrently with chemotherapy in limited disease small-cell lung cancer: A randomized phase II study of the Hellenic Cooperative Oncology Group (HeCOG)
(2001)Background: Concurrent platinum-etoposide chemotherapy given in combination with hyperfractionated thoracic radiation therapy (HTRT) in limited disease (LD) small cell lung cancer (SCLC) is associated with a high response ...
-
Article
Rituximab in combination with CNOP chemotherapy in patients withn previously untreated indolent non-Hodgkin's lymphoma
(2003)Rituximab, a chimeric monoclonal antibody, produces response rates of up to 73% in patients with previously untreated indolent non-Hodgkin's lymphoma (NHL), and has high activity when combined with chemotherapy. The purpose ...
-
Article
Weekly docetaxel in minimally pretreated cancer patients: A dose- escalation study focused on feasibility and cumulative toxicity of long-term administration
(1999)Background: Docetaxel is an agent with impressive clinical activity but a rather poor profile of toxicity when given every three weeks. Therefore, optimisation of its clinical use is highly warranted. This is a dose- ...